Study of Phosphate Levels in Patients With Chronic Kidney Disease

Conditions

• Chronic Kidney Disease

Interventions

• DRUG: 1.25 g PA21 (250 mg iron)
• DRUG: 5.0 g PA21 (1,000 mg iron)
• DRUG: 7.5 g PA21 (1,500 mg iron)
• DRUG: 10.0 g PA21 (2,000 mg iron)
• DRUG: 12.5 g PA21 (2,500 mg iron)
• DRUG: Sevelamer hydrochloride

Sponsor

Vifor Pharma